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Edited by Laszlo NagyAbstract Adiponectin is an adipose-derived hormone that has
anti-diabetic and anti-atherogenic eﬀects through interaction
with adiponectin receptors AdipoR1 and AdipoR2. We analyzed
the transcriptional regulation of AdipoR1 by insulin. Insulin re-
pressed the promoter activity of AdipoR1 in C2C12 myoblasts
via PI3K and Foxo1. Deletion studies demonstrated the presence
of a putative insulin-responsive region which is composed of a nu-
clear inhibitory protein (NIP) binding element. Mutation of the
NIP element abrogated the negative regulation of AdipoR1 pro-
moter by insulin. Insulin treatment could induce formation of a
protein complex that bound the NIP element. Collectively, our
data suggest that a repressive NIP element is involved in the neg-
ative regulation of AdipoR1 promoter by insulin.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Adiponectin/Acrp30 is an adipokine exclusively generated
by adipose tissue. Recent studies suggest that adiponectin
has anti-diabetic and anti-atherogenic activities through regu-
lation of lipid and glucose metabolism [1–4]. Adiponectin is a
30-kDa protein that contains 22 collagen repeats in the N-ter-
minal domain and a C-terminal TNF-a-like domain [5–8]. It
regulates lipid and glucose metabolism through stimulation
of glucose uptake and fatty acid oxidation via 5 0-AMP-acti-
vated protein kinase (AMPK), activation of peroxisome prolif-
erator-activated receptor-a (PPARa), and inhibition of hepatic
gluconeogenesis [3,9,10]. In humans, low serum concentration
of adiponectin has been shown to correlate with obesity, insu-
lin resistance, hyperinsulinaemia, and type 2 diabetes [11–13].
Adiponectin exerts its biological eﬀects by interacting with
adiponectin receptors AdipoR1 and AdipoR2. Both receptors
contain seven transmembrane domains that are diﬀerent from
classical G-protein-coupled receptors in structure and function
[14]. AdipoR1 is abundantly expressed in many tissues with a
relatively high level in skeletal muscle, whereas AdipoR2 is
predominantly expressed in the liver [14]. The expression level
of adiponectin receptors has been linked to insulin resistance in
human studies [15,16]. AdipoR1 expression in skeletal muscle
is increased in streptozotocin-induced diabetic mice, whereas*Corresponding author. Fax: +86 21 54920291.
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doi:10.1016/j.febslet.2008.08.037this eﬀect was reversed by insulin [17,18]. The inhibitory eﬀect
of insulin on AdipoR1 expression was proposed to be medi-
ated by phosphoinositide 3-kinase (PI3-kinase) and Foxo1
pathways [18,19]. However, how this regulation is executed
at the transcriptional level has not been elucidated.
We previously isolated AdipoR1 and AdipoR2 promoters
and found that the PPARc agonist rosiglitazone can interact
functionally with a GR element in the AdipoR2 promoter to
mediate the stimulation of AdipoR2 transcription in the liver
[20]. To address the potential regulation of adiponectin recep-
tors by insulin in the skeletal muscle, we analyzed the tran-
scriptional regulation of AdipoR1 and AdipoR2. We found
that AdipoR1 but not AdipoR2 was negatively regulated by
insulin in C2C12 myoblasts. Moreover, we found that a con-
sensus repressor element, termed nuclear inhibitory protein
(NIP), is required for the inhibitory eﬀect of insulin on Adi-
poR1 transcription.2. Materials and methods
2.1. Cell culture
C2C12 cells were grown in DMEM supplemented with 10% heat-
inactivated fetal bovine serum, 100 lg/ml streptomycin, and
100 units/ml penicillin. Transient cell transfection was performed using
Lipofectamine 2000 (Invitrogen, Carlsband, CA, USA). Insulin was
purchased from Sigma (St. Louis, MO, USA) and wortmannin was
from Calbiochem (San Diego, CA, USA).
2.2. RNA isolation and reverse transcription PCR (RT-PCR)
Total RNA prepared from C2C12 cells was reverse-transcribed with
oligo(dT) primer using M-MLV reverse transcriptase (Takara, Japan),
followed by PCR to detect the expression of AdipoR1, AdipoR2 and
glyceraldehyde-3-phosphate dehydrogenase (G3PDH). The sequences
of the PCR primers are as described before [20]. The ampliﬁcation con-
ditions were as follows: one cycle of denaturing at 94 C for 5 min,
annealing at 60 C for 40 s, and extension at 72 C for 40 s. This was
followed by 28 cycles of PCR. The reaction products were separated
on 2% agarose gel and stained with ethidium bromide. The band inten-
sity was quantiﬁed using the Dolphin-1D image program (Wealtec
Corp., Sparks, NV, USA).
2.3. Plasmids and luciferase assay
Expression vectors encoding Foxo1 and its mutants in pcDNA3 were
kindly provided by Dr. K.L. Guan and have been described previously
[21]. These constructs included the full-length cDNA of wild-type
Foxo1, the constitutively active phosphorylation-defective mutant
S319A, and a DNA binding-defective mutant H215R. C2C12 cells were
seeded in 24-well plates at a density of 2 · 105 cells/ml. After culturing
for 16–24 h, the cells were switched to fresh DMEMwithout serum and
transfected with plasmids using the Lipofectamine 2000. A renilla lucif-
erase vector, phRL-SV40 (Promega, Madison, WI, USA), was co-
transfected to monitor transfection eﬃciency. Twenty-four hours later,blished by Elsevier B.V. All rights reserved.
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of insulin. After treatment for 24 h, the cells were harvested by lysis with
PBS containing 0.1% Triton X-100 and 1 mmol/l phenylmethylsulfonyl
ﬂuoride (in a total volume of 100 ll). Ten microlitres of the lysate was
used in the dual luciferase assay by a luciferase assay kit (Kenreal,
Shanghai, China) with a luminometer (Berthold, Bad Wildbad, Ger-
many). The luciferase activity was normalized to the renilla luciferase
activity and triplicate transfections were carried out for each treatment.
At least three separate transfection experiments were performed for
each assay. Students t-test was used to analyze the luciferase data by
comparing the untreated and treated samples.
2.4. Electrophoretic mobility shift assay (EMSA)
Double-stranded oligonucleotides were labeled with [c-32P]dATP by
T4 polynucleotide kinase. For analysis of NIP binding, two probes were
used in EMSA: the DNA fragment spanning 474 bp to 459 bp of
AdipoR1 promoter with the sequence of 5 0-TTCAGGCTGCGAT-
AA-3 0 which contains the consensus NIP element, and the mutant se-
quence 5 0-TTCAGGCTAAGATAA-3 0 in which GC in the middle of
NIP element was replaced by AA. Nuclear protein extracts were pre-
pared as described [22]. The labeled probes (approx. 5 · 10 cpm) were
incubated with 2 lg of nuclear extract in a buﬀer containing ﬁnal con-
centrations of 4% (v/v) glycerol, 10 mmol/l Tris (pH7.5), 1 mmol/l
MgCl2, 0.5 mmol/l EDTA, 0.5 mmol/l dithiothreitol, 50 mmol/l NaCl
and 0.1 lg/ll poly(dI-dC) at room temperature for 10 min before addi-
tion of the probe. The binding reaction was incubated at room for
60 min, separated on a non-denaturing 4% (w/v) polyacrylamide gel
in 0.5 · TBE buﬀer (1 · TBE = 45 mmol/l Tris/borate/1 mmol/l EDTA)
and detected by autoradiography with the dried gel.Fig. 1. Regulation of AdipoR1 and AdipoR2 promoters by insulin. (A) The
activity. C2C12 myoblasts were transfected with the luciferase constructs of A
insulin and/or 100 nM of wortmannin as indicated for 24 h before dual lucifer
experiments as fold change ± SD. Students t-test was performed with the da
adiponectin receptors. C2C12 myoblasts were treated with or without 10 nM
speciﬁc primers for AdipoR1, AdipoR2 and G3PDH. The relative values o
G3PDH and shown as average ± SD. ** indicates P < 0.01.3. Results
3.1. Negative regulation of AdipoR1 promoter by insulin
To analyze the regulation of adiponectin receptors by insulin
at the transcriptional level, both AdipoR1 and AdipoR2 pro-
moters were linked to a luciferase reporter and transiently
transfected into C2C12 myoblasts. A renilla luciferase vector
driven by SV40 promoter was co-transfected to monitor the
transfection eﬃciency. As shown in Fig. 1A, when the lucifer-
ase constructs of the AdipoR1 or AdipoR2 promoter were
transfected into C2C12 myoblasts, we observed a signiﬁcant
reduction of AdipoR1 promoter activity by insulin. However,
the transcriptional activity of AdipoR2 promoter was not af-
fected by insulin. These data indicate that insulin is able to spe-
ciﬁcally repress the transcription of AdipoR1 but not AdipoR2
in C2C12 cells. To determine whether or not the insulin-in-
duced AdipoR1 promoter repression is mediated by PI3K
pathway, a PI3K inhibitor wortmannin was used to treat the
cells in the promoter assay (Fig. 1A). The basal transcriptional
activities of AdipoR1 and AdipoR2 promoters were not af-
fected by wormannin. However, the inhibitory eﬀect of insulin
on AdipoR1 promoter activity was abrogated upon wortman-
nin treatment. These results were consistent with previous
observation that implicated PI3K pathway in the negative reg-eﬀects of insulin and wortmanin on AdipoR1 and AdipoR2 promoter
dipoR1 and AdipoR2 promoters. The cells were treated with 10 nM of
ase assay. The data shown here are representative of three independent
ta and ** indicates P < 0.01. (B) Determination of the mRNA levels of
of insulin for 24 h and the total RNA was used for RT-PCR with
f adiponectin receptors for each sample were compared with those of
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inhibitory eﬀect of insulin on AdipoR1 promoter, we deter-
mined the mRNA levels of adiponectin receptors in C2C12
cells (Fig. 1B). Total RNA was isolated from the cells and used
in RT-PCR to analyze the levels of adiponectin receptors
mRNA. To monitor the relative RNA amounts used in the
experiment, the same RNA samples were also used in PCR
with primers speciﬁc for the housekeeping gene, G3PDH. Con-
sistent with the results observed with promoter assays, insulin
was able to suppress the mRNA level of AdipoR1 to about
50% but had no eﬀect of the mRNA of AdipoR2.
3.2. Foxo1 is involved in the insulin-dependent regulation on
AdipoR1 promoter
Foxo1 mediates insulin signaling as a substrate of Akt/pro-
tein kinase B and serum- and glucocorticoid-inducible kinase
(SGK) [23,24]. Foxo1 acts as an activator to enhance promoter
activity in the absence of insulin. Insulin-dependent phosphor-
ylation of Foxo1 leads to nuclear exclusion and inhibition of
Foxo1-dependent transcription [21,25,26]. It was previously re-
ported that insulin negatively regulates AdipoR1 expression
via inactivation of Foxo1 [18]. Therefore, we studied the eﬀect
of Foxo1 on the regulation of AdipoR1 promoter. C2C12
myoblasts were co-transfected with AdipoR1 promoter repor-
ter, pcDNA3 (as vector control) or the expression vector for
wild-type Foxo1. As shown in Fig. 2, we found that the basal
transcriptional activity of the reporter was increased signiﬁ-
cantly with the expression of wild-type Foxo1 and insulin
was also able to repress AdipoR1 promoter activity by
50%. The non-phosphorylatable mutant of Foxo1, S319A
[21], also caused an increase in AdipoR1 promoter activity,
but insulin could not inhibit the promoter activity anymore.
Meanwhile, we also studied a DNA binding-defective mutant
H215R of Foxo1 [21], and found that such mutation did not
aﬀect the basal activity of AdipoR1 promoter. However, insu-
lin completely lost its ability to suppress AdipoR1 transcrip-
tion in the presence of H215R. Taken together, these
ﬁndings suggest that Foxo1 is implicated in the negative regu-
lation of AdipoR1 promoter by insulin.Fig. 2. The eﬀect of Foxo1 on AdipoR1 promoter. C2C12 myoblasts
were transfected with AdipoR1 promoter, together with wild-type or
mutant Foxo1 as indicated. The cells were treated with or without
10 nM insulin for 24 h followed by dual luciferase assay. The fold
change of luciferase activity is shown as mean ± SD. Students t-test
was performed. ** indicates P < 0.01 and * for P < 0.05. S319A is a
constitutively active phosphorylation-defective mutant of Foxo1, and
H215 is a DNA binding-defective mutant of Foxo1.3.3. Identiﬁcation of an insulin-responsive region in the AdipoR1
promoter
To examine the region of AdipoR1 promoter responsive to
the inhibitory eﬀect of insulin, we cloned a series of deletion
constructs of AdipoR1 promoter and fused them to the lucif-
erase reporter. These deletion constructs were then transfected
into C2C12 myoblasts for luciferase assay. As shown in
Fig. 3A, there was a signiﬁcant inhibitory eﬀect by insulin with
the 3 kb and DA (484 bp upstream of the transcription ini-
tiation site) of AdipoR1 promoters. However, when AdipoR1
promoter was shortened to 464 bp upstream of the transla-
tion initiation site (DB construct), the insulin-mediated repres-
sion of the promoter was completely lost. Further deletions of
the promoter also led to loss of the inhibitory eﬀect by insulin
(DC–DF constructs). These data, therefore, suggest that the
promoter sequences between 484 bp (DB construct) and
464 bp (DC construct) contain a critical regulatory site(s)
that enables the promoter to be responsive to insulin repres-
sion in C2C12 cells.
To further identify the insulin-responsive region of AdipoR1
promoter, we analyzed a few more deletion mutants of the pro-
moter, from 484 bp to 464 bp relative to the translation ini-
tiation site. As shown in Fig. 3B, we found that both the
474 bp (DG) and 469 bp (DH) constructs were responsive
to insulin. These results indicated that the sequence between
469 bp and 464 bp was critical for the inhibitory activity
of insulin.
3.4. A nuclear inhibitory protein (NIP) binding element is
implicated in the negative regulation of AdipoR1 promoter
by insulin
After the characterization of the putative insulin-responsive
region of the AdipoR1 promoter, we analyzed the enclosed
nucleotide sequence in this area to determine the putative tran-
scription factor binding sites using the TESS program pro-
vided by the Computational Biology and Informatics
Laboratory at the University of Pennsylvania Schools of Med-
icine Engineering and Applied Science (http://www.cbil.upen-
n.edu). As a result, we found a consensus silencer element,
termed nuclear inhibitory protein (NIP) binding element in
this region (Fig. 4A) [27], instead of a classical insulin-respon-
sive element or Foxo1 binding element [24,28]. It is noteworthy
that the AdipoR2 promoter does not contain such a NIP ele-
ment in the corresponding region. We hypothesized that the
NIP element might be implicated in the inhibitory eﬀect of
insulin on the AdipoR1 receptor. To analyze the potential con-
tribution of this consensus sequence to the insulin-mediated
repression of AdipoR1 gene, we generated point mutations
of NIP sequence (mNIP) in which the GC sequence in the mid-
dle of NIP element was mutated to AA. As expected, the Adi-
poR1 promoter with mutations of the critical NIP sequence
was no longer responsive to the inhibitory eﬀect of insulin
(Fig. 4A).
As we found that Foxo1 is involved in the negative regula-
tion of AdipoR1 promoter by insulin (Fig. 2), we next deter-
mined whether or not the NIP element is required for such
regulation. Both the DH and mNIP promoter constructs were
used in a luciferase assay with co-expression of wild-type and
mutant Foxo1. As show in Fig. 4B, the eﬀects of these Foxo1
proteins on DH construct was similar to our observation with
the full-length AdipoR1 promoter. Both the wild-type and
non-phosphorylatable mutant of Foxo1 (S319A) could elevate
Fig. 3. Characterization of the insulin-responsive element in AdipoR1 promoter. (A) The left side of the ﬁgure illustrates the lengths of diﬀerent
promoter constructs with the number indicating the distance of the promoter in base pairs upstream of the translation initiation site. C2C12 cells
were transiently transfected with the various deletion constructs of the AdipoR1 promoter as indicated and co-transfected with renilla luciferase
vector. Twenty-four hours after transfection, the cells were treated with or without 10 nM insulin for 24 h and followed by dual luciferase assay. The
fold change of luciferase activity is shown as mean ± SD. Students t-test was performed and ** indicates P < 0.01. (B) Further characterization of the
insulin-responsive region of the AdiopR1 promoter as described for a. Note that deletion of ﬁve more bp in DB in comparison with DH led to
complete loss of the inhibitory eﬀect of insulin.
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insulin was only able to repress the transcriptional activity of
DH in the presence of wild-type Foxo1, but not S319. The
DNA binding-defective Foxo1 mutant H215R could not aﬀect
the basal activity of DH construct. However, expression of var-
ious Foxo1 plasmids had no eﬀect on the transcriptional activ-
ity of mNIP construct (Fig. 4B). Taken together, these data
suggest that insulin-mediated repression on AdipoR1 tran-
scription is mediated by a NIP element located in the insu-
lin-responsive region of the promoter. Furthermore, our data
indicate that the regulation of AdipoR1 promoter by Foxo1
is mediated by the NIP element.
3.5. Characterization of NIP binding by electrophoresis mobility
shift assay (EMSA)
We next used EMSA to further analyze the association of
potential transcription factors to the critical NIP element of
the AdipoR1 promoter. We analyzed whether insulin treat-
ment is able to induce formation of a protein complex that
binds to this critical region. C2C12 myoblasts were treated
with insulin for diﬀerent length of time and the nuclear extracts
were isolated for EMSA. The DNA fragment spanning
474 bp to 459 bp of AdipoR1 promoter that contains the
consensus NIP element was used as a probe in the experiment.
A mutated fragment, in which the GC sequence in the middle
of NIP sequence was replaced by AA, was also used in EMSA.As shown in Fig. 5, insulin treatment in these cells was able to
induce a time-dependent binding of nuclear proteins to this re-
gion. However, there was no binding with the mutant probe in
the experiment. These data, therefore, indicate that insulin is
able to induce formation of a protein complex that binds to
the NIP element, likely contributing to the repression of Adi-
poR1 promoter by insulin.4. Discussion
We have recently isolated the promoters of AdipoR1 and
AdipoR2 and characterized their regulation by PPAGc ago-
nists [20]. In this study, we analyzed the transcriptional regula-
tion of AdipoR1 and AdipoR2 by insulin in C2C12 myoblasts.
AdipoR1 expression was the highest in skeletal muscle both in
human and mouse [29], and was decreased in hyperglycemic
obese db/db mice [17]. Our results indicate that insulin was
able to repress the promoter activity of AdipoR1 but not Adi-
poR2 in C2C12 cells. Many genes related to glucose and lipid
metabolism were regulated by insulin through diﬀerent consen-
sus insulin response sequences (IRSs) [28,30,31]. Meanwhile, it
was recently reported that the insulin-dependent gene expres-
sions was partly mediated by phosphorylation and nuclear ex-
port of the forkhead transcription factor (Foxo1/FKHR) in a
PI3K-dependent pathway [21,26,32]. In our study, wortman-
Fig. 4. Mutation of the consensus NIP element abrogates insulin
responsiveness of the AdipoR1 promoter. (A) Luciferase assay was
performed with AdipoR1 promoter construct that contains nucleotide
mutations at the NIP element. The bottom panel depicts the predicted
NIP element in the AdipoR1 promoter. C2C12 cells were transfected
with DH as described in Fig. 3 or DH with point mutations within the
consensus NIP element (mNIP) in which the central GC was mutated
to AA. (B) Luciferase assays with AdipoR1 DH and mNIP constructs
together with the wild-type and mutant Foxo1. The experimental
condition was the same as Fig. 2. The fold change of luciferase activity
is shown as mean ± SD and ** indicates P < 0.01.
Fig. 5. Insulin treatment induced formation of a NIP-binding protein
complex. Nuclear extracts from C2C12 cells treated with 10 nM of
insulin for 0, 1, 4, and 8 h were used in EMSA with the 32P-labeled
oligonucleotide probes that contains a NIP element in the middle
(AdipoR1 NIP: 5 0-ttcaggctgcgataa-3 0; mutant NIP: 5 0-ttcaggctaagat-
aa-3 0). The NIP-binding complex induced by insulin treatment is
indicated.
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on AdipoR1 promoter activity. This ﬁnding is supported by
the work of Inukai et al. showing that the PI3K is required
for the regulation of AdipoR1 expression upon insulin signal-
ing [17]. As Foxo1 is negatively regulated by the PI3K and
PKB/Akt pathway, we analyzed the eﬀects of Foxo1 on insu-
lin-regulated AdipoR1 promoter activity. We found that over-
expression of Foxo1 was able to signiﬁcantly increase the basal
promoter activity of AdipoR1 gene and insulin retained its
inhibitory eﬀect on the promoter. The constitutively active
non-phosphorylable mutant of Foxo1 (S319A) also caused a
signiﬁcant increase in the basal AdipoR1 promoter activity.However, insulin could not repress the promoter activity when
S319A was overexpressed, consistent with the notion that
S319A mutant cannot be phosphorylated by insulin signaling.
The increase of basal activity of AdipoR1 promoter by S319A
mutant could be caused by displacement of endogenous Foxo1
by overexpression of the mutant protein, leading to a de-
creased inhibition of the promoter by endogenous Foxo1.
Meanwhile, overexpression of the DNA binding-defective mu-
tant H215R could not change the basal AdipoR1 promoter
activity, nor be responsive to insulin. The loss of insulin-
responsiveness by H215R overexpression is likely caused by
abrogation of insulin-induced phosphorylation of endogenous
Foxo1 by overexpressed mutant protein. Nevertheless, our re-
sults conﬁrmed at the transcription of AdipoR1 are negatively
regulated by insulin via the PI3K and Foxo1 pathway.
Our detailed molecular analyses have characterized a puta-
tive insulin-responsive region in the AdipoR1 promoter. Inter-
estingly, this region does not contain a classical insulin
response sequences (IRSs) or a Foxo1 binding site. Instead,
the insulin-responsive region in the AdipoR1 promoter con-
tains a strong repressor element, termed nuclear inhibitory
protein (NIP). NIP was ﬁrst reported at the region between
271 bp and 250 bp of IL-3 promoter [27]. The critical se-
quence of NIP is 5 0-GCTGCCATG-3 0 and acts as an AP-1 re-
lated repressor of transcription in the IL-3 promoter and
stromelysin promoter [33]. The NIP sequence is able to specif-
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AP2 sequence-recognizing factor (ASRF) is a component of
one of the four complexes, which is required for the inhibitory
function of NIP element in the IL-3 promoter [34]. Urokinase-
type plasminogen activator enhancer Factor 3 (UEF3) was
also reported to bind NIP element in IL-3 promoter owing
to the sequence homology between NIP and the UEF3-binding
sequence [35]. We found that mutation of critical sequences
within the NIP element lost the responsiveness to insulin on
the AdipoR1 promoter. Furthermore, we found that insulin
is able to induce formation of a protein complex that binds
the NIP sequence but not the mutated one in the AdipoR1
promoter. Therefore, these data strongly indicate that the con-
sensus NIP element is implicated in the negative regulation of
AdipoR1 promoter by insulin. In addition, our data indicate
that the Foxo1-mediated regulation of AdipoR1 promoter is
via the NIP element as mutation of the element leads to loss
of responsiveness of the promoter to Foxo1. We analyzed
whether or not Foxo1 is present in the protein complex by a
supershift assay in EMSA using a speciﬁc antibody against
Foxo1. We found that the antibody could not change the
NIP-bound protein complex (data not shown), suggesting that
Foxo1 may not directly bind the NIP element. Considering the
functional involvement of NIP element in the transcriptional
regulation of AdipoR1 by insulin, it will be of great impor-
tance in the future to identify the nature of protein(s) that
binds the NIP element and mediates the repressive activity of
insulin on AdipoR1 promoter. Nevertheless, our studies re-
ported for the ﬁrst time that NIP element is implicated in the
repressive action of insulin, thus highlighting the complexity
of transcriptional regulation downstream of insulin signaling.Conﬂict of interest statement
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